Stock Analiz

Mirum Pharmaceuticals, Inc. (MIRM) financials: revenue, earnings and cash flow

Fiscal 2019–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Net income in fiscal 2025 was -$23M, a net margin of -4.5%; the highest of the period.

Over the twelve months to September 30, 2026, revenue was $671M and net income -$904M.

Free cash flow was $55M in fiscal 2025 and positive in 2 of the 7 years shown.

The diluted share count rose 337% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2020: $020202021: $19M20212022: $77M20222023: $186M20232024: $337M20242025: $521M2025$521M
Net income
2019: -$53M20192020: -$103M20202021: -$84M20212022: -$136M20222023: -$163M20232024: -$88M20242025: -$23M2025-$23M
Free cash flow
2019: -$40M20192020: -$89M20202021: -$133M20212022: -$120M20222023: -$71M20232024: $9M20242025: $55M2025$55M
EPS (diluted)
2019: $-4.5820192020: $-4.0920202021: $-2.7720212022: $-4.0220222023: $-4.0020232024: $-1.8520242025: $-0.472025$-0.47

Income statement

Fiscal yearTTM2025202420232022202120202019
Revenue$671M$521M$337M$186M$77M$19M$0—
Gross profit————————
Operating income-$896M-$22M-$88M-$109M-$131M-$173M-$104M-$55M
Net income-$904M-$23M-$88M-$163M-$136M-$84M-$103M-$53M
EPS (diluted)$-14.47$-0.47$-1.85$-4.00$-4.02$-2.77$-4.09$-4.58
R&D$352M$186M$141M$103M$107M$131M$82M$43M
Revenue growth—+54.7%+80.8%+141.9%+302.7%———

Cash flow

Fiscal yearTTM2025202420232022202120202019
Operating cash flow-$271M$56M$10M-$71M-$120M-$133M-$89M-$39M
Capital spending-$3M-$954000-$993000-$109000-$278000-$24000-$225000-$281000
Free cash flow-$274M$55M$9M-$71M-$120M-$133M-$89M-$40M
Dividends paid—$0$0$0$0$0$0$0
Buybacks————————
Stock-based pay$119M$71M$48M$35M$27M$23M$13M$6M

Balance sheet

Fiscal yearTTM2025202420232022202120202019
Cash—$383M$280M$286M$152M$157M$232M$117M
Debt—$10M$10M$2M$2M$3M$3M$4M
Equity—$315M$226M$249M$142M$120M$172M$130M
Total assets—$843M$671M$647M$353M$295M$241M$147M
Shares (diluted)66M50M48M41M34M30M25M11M

Margins and returns

Fiscal yearTTM2025202420232022202120202019
Gross margin————————
Operating margin-133.6%-4.2%-26.0%-58.6%-170.3%-906.1%——
Net margin-134.8%-4.5%-26.1%-87.7%-176.0%-438.8%——
FCF margin-40.8%10.5%2.8%-38.1%-156.3%-693.8%——
ROIC—-5.4%-29.4%-34.4%-86.9%-111.5%-47.0%-32.3%
ROE—-7.4%-39.0%-65.7%-95.5%-69.9%-60.0%-40.3%

Frequently asked questions

What is Mirum Pharmaceuticals’s annual revenue?

$521M in fiscal 2025 and $671M over the twelve months to September 30, 2026.

How much profit does Mirum Pharmaceuticals make?

Net income was -$23M in fiscal 2025 (net margin -4.5%).

Is Mirum Pharmaceuticals’s revenue growing?

Yes: revenue rose 54.7% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.